Potential alternative drug treatment for bone giant cell tumor

Zhangxin Chen, Cong Zhang, Haisen Hong, Wenbin Xu, Mo Sha, Zhenqi DingFrontiers in Cell and Developmental Biology 2023 · DOI

Abstract

Background: Bone giant cell tumor (BGCT) is a locally aggressive primary bone tumor. While denosumab is the current standard systemic treatment, its use is limited by high local recurrence rates after discontinuation and potential long-term side effects. This study utilizes bioinformatics to identify alternative genetic targets and potential drugs for BGCT treatment.

Methods: A multi-stage pipeline was employed, starting with text mining via pubmed2ensembl to identify genes shared between BGCT and fracture healing. These genes underwent functional enrichment analysis (DAVID) and protein-protein interaction (PPI) network modeling (STRING/Cytoscape). Finally, hub genes were queried against the Drug Gene Interaction Database (DGIdb) to identify therapeutic candidates.

Results: The study identified 123 genes common to BGCT and fracture healing. Further analysis narrowed this to seven central hub genes: ANGPT2, COL1A1, COL1A2, CTSK, FGFR1, NTRK2, and PDGFB. Interaction analysis identified 17 potential drugs, including 15 antineoplastic agents, one anti-osteoporosis drug, and one anti-influenza drug.

Conclusion: The identified hub genes and 17 candidate drugs—six of which are already FDA-approved for other indications—represent promising avenues for drug repositioning to improve BGCT outcomes.

Introduction

Bone Giant Cell Tumor (BGCT) is a locally aggressive primary bone tumor that typically affects the epiphyses of long bones in young adults. Although rarely metastatic, BGCT is highly destructive to local bone tissue. The current pharmacological "gold standard" is denosumab, a monoclonal antibody that inhibits bone resorption. However, denosumab is often a temporary solution; local recurrence rates spike once treatment stops, and long-term use is associated with complications such as osteonecrosis of the jaw. There is a critical clinical need for alternative therapeutic targets that can manage the tumor more effectively or provide options when denosumab is unsuitable.

Methodology

To address this, researchers developed a bioinformatics pipeline to bridge the gap between existing literature and clinical application:

  1. Text Mining: Using the pubmed2ensembl service, the team identified genes associated with "Bone Giant-cell tumor" and "Fracture healing." The rationale is that both processes involve intense bone remodeling and shared signaling pathways.
  2. Functional Enrichment: The DAVID database was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses to understand the biological roles of overlapping genes.
  3. Network Analysis: Protein-Protein Interaction (PPI) networks were constructed using STRING and Cytoscape. The MCODE plugin was used to extract highly connected "hub" genes.
  4. Drug-Gene Interaction: Hub genes were queried against the Drug Gene Interaction Database (DGIdb) to find existing drugs that target these proteins.
Overall data mining strategy workflow for identifying BGCT therapeutic targets.

Key Insights and Results

The Fracture Healing Proxy

A central premise of this study is that fracture healing serves as a biological template for BGCT. Both involve massive osteoclastic activity and bone repair attempts. By identifying 123 genes common to both processes, the researchers highlighted the dysregulated pathways driving tumor progression.

Venn diagram showing the 123 genes shared between fracture healing and BGCT.

Pathway and Hub Gene Identification

KEGG analysis identified the PI3K-Akt and MAPK signaling pathways as strongly correlated with BGCT. From the initial pool of 123 genes, seven were identified as central "hubs" of the molecular network: ANGPT2, COL1A1, COL1A2, CTSK, FGFR1, NTRK2, and PDGFB. Experimental validation using qRT-PCR on patient tissues confirmed the significant upregulation of five of these genes (NTRK2, FGFR1, PDGFB, COL1A1, and COL1A2) in tumor samples compared to healthy controls.

Drug Repositioning Potential

The analysis identified 17 drugs targeting these hub genes. Notably, six of these—including Sunitinib and Nintedanib—are already FDA-approved for other conditions. This suggests a significant opportunity for drug repositioning, which could shorten the timeline for clinical trials in BGCT.

Conclusion and Future Directions

This study provides a molecular roadmap for alternative BGCT treatments. By targeting hub genes involved in both bone remodeling and tumor growth, clinicians may find alternatives to denosumab. However, the study is limited by a small validation cohort (n=12) and a lack of functional in vitro or in vivo assays. Future research should focus on testing the top-tier FDA-approved candidates in clinical settings, particularly for patients who are non-responsive to current therapies.

Summary updated

Abstract

<b>Background:</b> Bone giant cell tumor (BGCT) is one of the world's major disease types of locally aggressive bone tumors. In recent years, denosumab treatment has been introduced before curettage surgery. However, the current therapeutic was practical only sometimes, given the local recurrence effects after discontinuation of denosumab. Due to the complex nature of BGCT, this study aims to use bioinformatics to identify potential genes and drugs associated with BGCT. <b>Methods:</b> The genes that integrate BGCT and fracture healing were determined by text mining. The gene was obtained from the pubmed2ensembl website. We filtered out common genes for the function, and signal pathway enrichment analyses were implemented. The protein-protein interaction (PPI) networks and the hub genes were screened by MCODE built-in Cytoscape software. Lastly, the confirmed genes were queried in the Drug Gene Interaction Database to determine potential genes and drugs. <b>Results:</b> Our study finally identified 123 common specific genes in bone giant cell tumors and fracture healing text mining concepts. The GO enrichment analysis finally analyzed 115 characteristic genes in BP, CC, and MF. We selected 10 KEGG pathways and identified 68 characteristic genes. We performed protein-protein interaction analysis (PPI) on 68 selected genes and finally identified seven central genes. In this study, these seven genes were substituted into drug-gene interactions, and there were 15 antineoplastic drugs, 1 anti-involving drug, and 1 anti-influenza drug. <b>Conclusion:</b> The 7 genes (including <i>ANGPT2</i>, <i>COL1A1</i>, <i>COL1A2</i>, <i>CTSK</i>, <i>FGFR1</i>, <i>NTRK2</i>, and <i>PDGFB</i>) and 17 drugs, which have not been used in BGCT, but 6 of them approved by the FDA for other diseases, could be potential genes and drugs, respectively, to improve BGCT treatment. In addition, the correlation study and analysis of potential drugs through genes provide great opportunities to promote the repositioning of drugs and the study of pharmacology in the pharmaceutical industry.
BibTeX
@inproceedings{chen2023potential,
  author = {Zhangxin Chen and Cong Zhang and Haisen Hong and Wenbin Xu and Mo Sha and Zhenqi Ding},
  title = {{Potential alternative drug treatment for bone giant cell tumor}},
  booktitle = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  doi = {10.3389/fcell.2023.1193217},
}
Figure